Pemetrexed-Carboplatin Adjuvant Chemotherapy With or Without Gefitinib in Resected Stage IIIA-N2 Non-Small Cell Lung Cancer Harbouring EGFR Mutations: A Randomized, Phase II Study
Explore this paper's citation graph
Summary
The administration of gefitinib following PC adjuvant therapy shows significant improvement in DFS in patients with resected stage IIIA-N2 NSCLC harbouring EGFR mutations.
- Type
- article
- Published
- 2014-03-01
- Cited by
- 94
- References
- 29
- OpenAlex
- https://openalex.org/W24585406
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:34655318
Keywords
Legislation, Political science, Class (philosophy), Norwegian, Danish
References
- Gefitinib does not improve survival when combined with paclitaxel and carboplatin chemotherapy in people with advanced non-small-cell lung cancer.
- Revisions in the International System for Staging Lung Cancer.
- Chemotherapy for patients with non-small cell lung cancer: the surgical setting of the Big Lung Trial.
- Impact on disease-free survival of adjuvant erlotinib or gefitinib in patients with resected lung adenocarcinomas that harbor epidermal growth factor receptor (EGFR) mutations
- Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer.
- Epidermal growth factor receptor mutation status and adjuvant chemotherapy in resected advanced non-small-cell lung cancer.
- Gefitinib versus placebo in completely resected non-small-cell lung cancer: results of the NCIC CTG BR19 study.
- Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group.
- Risk of cerebral metastases for postoperative locally advanced non-small-cell lung cancer.
- Phase III study by the Norwegian lung cancer study group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer.
- Global cancer statistics
- Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1.
- Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.
- Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer.
- Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA non-small-cell Lung cancer.
- Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2.
- Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer.
- Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial.
- Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR.
- Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy.
Cited by
- EGFR: The Paradigm of an Oncogene-Driven Lung Cancer
- Adjuvant molecularly targeted therapy-epidermal growth factor tyrosine kinase inhibition and beyond.
- EGFR-TKIs in adjuvant treatment of lung cancer: to give or not to give?
- Germline determinants of clinical outcome of cutaneous melanoma
- Epidermal growth factor receptor tyrosine kinase inhibitors in early-stage nonsmall cell lung cancer
- Meta-Analysis of EGFR Tyrosine Kinase Inhibitors Compared with Chemotherapy as Second-Line Treatment in Pretreated Advanced Non-Small Cell Lung Cancer
- A Retrospective Study of Stage I to IIIa Lung Adenocarcinoma After Resection: What Is the Optimal Adjuvant Modality for Patients With an EGFR Mutation?
- Personalized treatment of early-stage non-small-cell lung cancer: the challenging role of EGFR inhibitors.
- Icotinib, a selective EGF receptor tyrosine kinase inhibitor, for the treatment of non-small-cell lung cancer.
- Medical management of lung cancer: Experience in China
- Defining the Role of Tyrosine Kinase Inhibitors in Early Stage Non-Small Cell Lung Cancer
- Efficacy of EGFR Tyrosine Kinase Inhibitors in the Adjuvant Treatment for Operable Non-small Cell Lung Cancer by a Meta-Analysis.
- 非小细胞肺癌术后辅助化疗研究进展
- Eventual role of EGFR-tyrosine kinase inhibitors in early-stage non-small-cell lung cancer.
- Adjuvant therapy for nonsmall cell lung cancer: recent advances and future perspectives
- Tyrosine Kinase Inhibitors for the Elderly
- Targeted therapy for locally advanced non-small-cell lung cancer with EGFR mutation
- Retrospective study of adjuvant icotinib in postoperative lung cancer patients harboring epidermal growth factor receptor mutations
- Targeted therapy for localized non-small-cell lung cancer: a review
- Have adjuvant tyrosine kinase inhibitors lost their shine?
Related papers
No related papers recorded.